Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Get a deep dive into using method references in your Java programs, including stream operations, event listeners, and constructors and factories.

The United States leads in AI, but staying ahead requires scaling compute, energy, and capital. This commentary previews new Energy Security and Climate Change research on AI infrastructure, domestic ...

Those additional layers will add new reliability issues a number of incremental reliability challenges, but the NAND flash industry has been steadily increasing the stack height for nearly a decade.

Recursion states that REC-1245 is the first program using the company’s end-to-end AI platform, spanning discovery, biology, chemistry, and the clinic. According to Chris Gibson, CEO of ...

Recursion strengthened its AI focus by snapping up two companies in the AI-driven drug discovery space.

On May 8, Recursion Pharmaceuticals (RXRX -2.35%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.